Article

Transcriptomic Signature and PROTAC Strategy Revealed Histone Lysine Demethylase as a Target of Anticancer Activity of Deferiprone

2025-10-15

Abstract excerpt

Deferiprone (DFP) is an iron chelator approved for treating iron overload in thalassemia patients. Recent observations have suggested that DFP has promising anticancer activities ascribed to several mechanisms including reduction of the intracellular free labile iron and zinc ion pools and inhibition of the activities of other intracellular targets, including ribonucleotide reductase (RNR). We previously reported...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 11971ac1-8f27-578c-96d5-f4bb5eecc48a
DOI: 10.1101/2025.10.13.682199

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Transcriptomic Signature and PROTAC Strategy Revealed Histone Lysine Demethylase as a Target of Anticancer Activity of DeferiproneDOI 10.1101/2025.10.13.682199Read

The Clinically Used Iron Chelator Deferasirox is an Inhibitor of Epigenetic JumonjiC Domain-Containing Histone DemethylasesSemantic proximity Read

Pan‐cancer analysis of iron metabolic landscape across the Cancer Genome AtlasSemantic proximity Read

Modulation of intracellular iron metabolism by iron chelation affects chromatin remodeling proteins and corresponding epigenetic modifications in breast cancer cells and increases their sensitivity to chemotherapeutic agentsSemantic proximity Read

ADAR1 Regulates Lipid Remodeling to Dictate Ferroptosis SensitivitySemantic proximity Read

Transcriptional regulation of amino acid metabolism by KDM2B, in the context of ncPRC1.1 and in concert with MYC and ATF4Semantic proximity Read

New Iron Metabolic Pathways and Chelation Targeting Strategies Affecting the Treatment of All Types and Stages of CancerSemantic proximity Read

Heterogeneity of Response to Iron-Based Metallodrugs in Glioblastoma Is Associated with Differences in Chemical Structures and Driven by FAS Expression Dynamics and Transcriptomic SubtypesSemantic proximity Read

The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1Semantic proximity Read

Mapping the genetic landscape of iron metabolism uncovers the SETD2 methyltransferase as a modulator of iron fluxSemantic proximity Read

Computational Analysis of Iron-binding Proteins in the Mutational Landscape of Cancer.Semantic proximity Read

The deubiquitinase USP24 suppresses ferroptosis in triple-negative breast cancer by stabilizing DHODH proteinSemantic proximity Read

Deferasirox-Dependent Iron Chelation Enhances Mitochondrial Dysfunction and Restores p53 Signaling by Stabilization of p53 Family Members in Leukemic CellsSemantic proximity Read